In this issue:
- Changes in prognosis of the Danish MS population over time
- Impact of DMTs on evolving tissue damage in iron rim lesions
- MS disease burden below the clinical threshold
- Association between ambulatory disability and CNS pathology in MS
- A scoring system to guide the switch from first- to second-line therapy in MS
- Safety and efficacy of ocrelizumab in patients with active relapsing MS
- Safety and efficacy of different dosages of rituximab for NMOSD
- New and emerging DMTs and stem cell therapy for MS
- Management of migraine in MS patients
- Postmarketing adverse effects of oral DMTs
Please login below to download this issue (PDF)